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Dr Lorente and colleagues [1] report on the interesting 
association between serum soluble CD40 ligand (sCD40L) 
levels and mortality in patients with sepsis. Some 
variables that can inﬂ   uence outcome in sepsis were 
accounted for in their analysis. However, the amount of 
transfused blood products, which may inﬂ  uence levels of 
sCD40L, was not reported.
sCD40L accumulates to biologically relevant levels 
during storage of blood products [2,3], in particular of 
platelet products. Following transfusion, blood products 
can induce an inﬂ   ammatory reaction - by activating 
CD40-positive cells - associated with the occurrence of 
acute lung injury and other potential serious 
compli  cations [3]. Levels of sCD40L were also found to 
be elevated in patients with lung injury following 
transfusion [2]. Even more, transfusion itself contributes 
to mortality in the critically ill [4], as well as to adverse 
outcome of sepsis [5]. Taken together, we suggest that 
blood trans  fusion could have potentially inﬂ  uenced both 
serum sCD40L levels and outcome in the study 
performed by Lorente and colleagues. Th  e  authors  state 
that modulation of sCD40L levels could represent a 
therapeutic target. Would it not be more appropriate to 
question whether sCD40L from (stored) blood products 
contributed to elevated serum levels in their trial, before 
embarking on therapeutic interventions?
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We read with interest the letter by Tuinman and 
Juﬀ  ermans discussing our article recently published in 
Critical Care [1] showing that circulating levels of 
sCD40L were associated with mortality in sepsis.
As they stated, the lack of data about blood transfusion 
is a limitation of our study. In a recently published retro-
spective cohort study of patients with sepsis by Juﬀ  er-
mans and colleagues [5], it was found that transfusion of 
red blood cells or platelets, and the storage time of red 
blood cells were associated with the development of 
nosocomial bacterial infection. On the other hand, 
another study found that all blood components contained 
higher levels of sCD40L than fresh plasma (with the 
highest concentration in platelet concentrates) and that 
circulating sCD40L levels were higher in patients with 
lung injury following transfusion [2]. In addition, CD40L 
derived from platelets is a potent activator of neutrophils 
and mediates sepsis-induced neutrophil recruitment and 
lung edema in mice [6].
Despite this limitation, the results of our study (the 
largest series reporting data about sCD40L in patients 
with severe sepsis) suggest that sCD40L may be of 
pathophysiological signiﬁ   cance in sepsis due to non-
survivor patients showing higher sCD40L levels at the 
moment of diagnosis of severe sepsis than survivor 
patients. Th   us, we think it could be interesting to conduct 
more research on the role of sCD40L in sepsis, and 
additionally to study the inﬂ  uence of blood transfusion 
on sCD40L levels and patient prognosis.
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